Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial.

Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial. Cancer. 2019 09 15; 125(18):3208-3218.

View in: PubMed

subject areas

Adult
Aged
Aged, 80 and over
Antineoplastic Agents, Immunological
Disease Progression
Female
Head and Neck Neoplasms
Humans
Lung Neoplasms
Lymph Nodes
Male
Middle Aged
Neoplasm Recurrence, Local
Treatment Outcome

authors with profiles

Everett E. Vokes